Islatravir
Names | |
---|---|
IUPAC name
2′-Deoxy-4′-ethynyl-2-fluoroadenosine
| |
Systematic IUPAC name
(2R,3S,5R)-5-(6-Amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol | |
Other names
EFdA; MK-8591; 4′-Ethynyl-2-fluoro-2′-deoxyadenosine
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C12H12FN5O3 | |
Molar mass | 293.258 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine, EFdA, or MK-8591) is an investigational drug for the treatment of
HIV infection.[1] It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI).[2] Merck is developing a subdermal drug-eluting implant to administer islatravir.[3][4]
In 2021, FDA placed a partial clinical hold for several studies under Islatravir.[5] The reason was a decline in CD4 T cells under therapy. Merck announced to restart the study program in 2023 with a decreased dose, however studies of islatravir for pre-exposure prophylaxis (PrEP) will be discontinued.[6]
In 2024, results from a phase II study combining islatravir with lenacapavir indicated that the regimen shows promise as a possible weekly oral regimen.[7]
Biological activity
Islatravir has activity against HIV in
animal models,[8] and is being studied clinically for HIV treatment and prophylaxis.[9] Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that unlike other such inhibitors, inhibits HIV through multiple mechanisms,[8] providing rapid suppression of the virus, when tested in macaques and mice.[10] Nevertheless, there are HIV strains resistant to islatravir and research is ongoing.[11][12]
References
- PMID 18487070.
- PMID 29689540.
- ^ "Someday, an Arm Implant May Prevent H.I.V. Infection for a Year". New York Times. July 23, 2019.
- ^ "Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant" (Press release). July 23, 2019.
- ^ "Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP". aidsmap.com. Retrieved 2023-05-02.
- ^ "Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection". Merck. Retrieved 10 March 2024.
- ^ Highleyman, Liz (6 March 2024). "Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment". Aidsmap. Retrieved 10 March 2024.
- ^ PMID 24970894.
- ^ Grobler, Jay (February 22–25, 2016). Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis. Boston, Massachusetts. Conference on Retroviruses and Opportunistic Infections. 98.
- PMID 25941222.
- ^ Bruno Marchand. "The Crystal Structure of EFdA‐Resistant HIV‐1 Reverse Transcriptase Reveals Structural Changes in the Polymerase Active Site" (PDF).
- PMID 27489345.